What's New

Last Posted: Jan 18, 2024

• Serum Calretinin and Genetic Variability as a Prognostic and Predictive Factor in Malignant Mesothelioma.
  Cita Zupanc, et al. International journal of molecular sciences 2024 0 (1)
• The association of genetic factors with serum calretinin levels in asbestos-related diseases.
  Cita Zupanc, et al. Radiology and oncology 2023 0 (4) 473-486
• The role of single nucleotide polymorphisms related to iron homeostasis in mesothelioma susceptibility after asbestos exposure: a genetic study on autoptic samples.
  Pierangela Grignani, et al. Frontiers in public health 2023 0 1236558
• Comprehensive bioinformatics analysis of the role of VWF in the tumor microenvironment of malignant mesothelioma.
  Jiren Weng, et al. Medicine 2023 0 (41) e35579
• Genetic analysis of familial predisposition in the pathogenesis of malignant pleural mesothelioma.
  Akarsu Muhittin, et al. Journal of cancer research and clinical oncology 2023 0
• A study of somatic BRCA variants and their putative effect on protein properties in malignant mesothelioma.
  Krishnamurthy Kritika, et al. Pleura and peritoneum 2023 0 (1) 19-25
• Malignant Mesothelioma, BAP1 Immunohistochemistry, and VEGFA: Does BAP1 Have Potential for Early Diagnosis and Assessment of Prognosis?
  Pulford Emily, et al. Disease markers 2017 0 1310478
• Malignant Peripheral Nerve Sheath Tumor in a Patient With BAP1 Tumor Predisposition Syndrome.
  Kaszuba Megan C, et al. World neurosurgery 2017 0 362-364
• Comparison of Germline versus Somatic BAP1 Mutations for Risk of Metastasis in Uveal Melanoma.
  Ewens K G, et al. BMC cancer 2018 0 (1) 1172
• Multigene panel sequencing of established and candidate melanoma susceptibility genes in a large cohort of Dutch non-CDKN2A/CDK4 melanoma families.
  Potjer Thomas P, et al. International journal of cancer 2018 0 (10) 2453-2464
• BAP1 loss is unusual in well-differentiated papillary mesothelioma and may predict development of malignant mesothelioma.
  Lee Hee Eun, et al. Human pathology 2018 0 168-176
• Clinical Implications of Real-time Integrative Sequencing in Management of Patients With Suspected Germline BAP1 Mutations.
  Sengupta Shayan, et al. Journal of pediatric hematology/oncology 2018 0 (4) e263-e265
• Molecular analysis of an asbestos-exposed Belgian family with a high prevalence of mesothelioma.
  Hylebos Marieke, et al. Familial cancer 2018 0 (4) 569-576
• Loss of BAP1 in Pheochromocytomas and Paragangliomas Seems Unrelated to Genetic Mutations.
  Maffeis Valeria, et al. Endocrine pathology 2019 0 (4) 276-284
• NLRP3 and CARD8 polymorphisms influence risk for asbestos-related diseases.
  Franko Alenka, et al. Journal of medical biochemistry 2020 0 (1) 91-99
• Evaluation of soluble mesothelin-related peptides and MSLN genetic variability in asbestos-related diseases.
  Goricar Katja, et al. Radiology and oncology 2020 0 (1) 86-95
• Meningiomas in Patients With Malignant Pleural Mesothelioma Harboring Germline BAP1 Mutations.
  Hu Zishuo I, et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2021 0 (3) 461-466
• Novel LRRK2 mutations and other rare, non-BAP1-related candidate tumor predisposition gene variants in high-risk cancer families with mesothelioma and other tumors.
  Cheung Mitchell, et al. Human molecular genetics 2021 0 (18) 1750-1761
• Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study.
  Calabrò Luana, et al. The Lancet. Respiratory medicine 2021 0 (9) 969-976
• Correlation of MET-Receptor Overexpression with MET Gene Amplification and Patient Outcome in Malignant Mesothelioma.
  Santoni-Rugiu Eric, et al. International journal of molecular sciences 2021 0 (23)
• Expression of EGFR and conformational forms of EGFR in malignant pleural mesothelioma and its impact on survival.
  Chia Puey Ling, et al. Lung cancer (Amsterdam, Netherlands) 2021 0 35-41
• The role of polymorphisms in glutathione-related genes in asbestos-related diseases.
  Franko Alenka, et al. Radiology and oncology 2021 1
• The influence of genetic variability in IL1B and MIR146A on the risk of pleural plaques and malignant mesothelioma.
  Piber Petra, et al. Radiology and oncology 2020 10 (4) 429-436
• Genetic predisposition for malignant mesothelioma: A concise review.
  Betti Marta et al. Mutation research 7811-10
• Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group.
  Husain Aliya Noor et al. Archives of pathology & laboratory medicine 2018 Jan 142(1) 89-108
• Families with BAP1-Tumor Predisposition Syndrome in The Netherlands: Path to Identification and a Proposal for Genetic Screening Guidelines.
  Chau Cindy et al. Cancers 2019 Aug 11(8)
• Evaluation of Matrix Metalloproteinase 9 Serum Concentration as a Biomarker in Malignant Mesothelioma.
  Štrbac Danijela, et al. Disease markers 2019 0 1242964
• Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy.
  Hassan Raffit, et al. Proceedings of the National Academy of Sciences of the United States of America 2019 4
• The influence of genetic variability of DNA repair mechanisms on the risk of malignant mesothelioma.
  Levpuscek Kristina, et al. Radiology and oncology 2019 3
• Genetic polymorphisms in aquaporin 1 as risk factors for malignant mesothelioma and biomarkers of response to cisplatin treatment.
  Senk Barbara, et al. Radiology and oncology 2019 3 (1) 96-104

More